← All trials
NCT03283319
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2017
- Primary completion
- Dec 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 360
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Department of Health and Human ServicesLead sponsor
- Rochester Clinical ResearchOverall official - principal investigator
- Central Kentucky Research Assoc, IncOverall official - principal investigator
- Heartland Research Associates, LLCOverall official - principal investigator
- Johnson County Clin-TrialsOverall official - principal investigator
- Rho, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.